Investment
Features
FeesSafety
Academy
More
Pluang+

Compare F5 Inc (FFIV) vs Tilray Brands Inc (TLRY) Price & Performance

F5 IncTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

F5 Inc vs Tilray Brands Inc — how do they compare? F5 Inc trades at $403.62 (market cap $23.79B), while Tilray Brands Inc trades at $4.41 (market cap $541.36M). The key difference: F5 Inc is far larger — about 43.9× Tilray Brands Inc's market cap, and F5 Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.

FFIVTLRY
Market Cap
$23.79B$541.36M
Sector
TechnologyHealth
52-Week High
$431.26$21.00
52-Week Low
$223.99$4.31
Enterprise Value
$22.60B$638.50M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

F5 Inc

F5 Networks (FFIV) trades at $419.00, down 2.84% on the day, but remains in a bullish technical trend above key support levels. The company demonstrates strong fundamental momentum with revenue growth to $3.09B in 2025 and consistent earnings beats, including a recent Q1 2026 EPS of $3.90 against a $3.46 expectation. Recent news highlights strategic expansion into AI security, including the acquisition of SurePath AI (GeekWire, 2026-06-26).

The outlook is supported by robust profitability and strategic positioning in application security, but elevated valuation multiples (P/E 34.61, P/S 7.6) and a high current price relative to the analyst consensus target of $397.00 present near-term valuation risk. The primary investment opportunity lies in the company's execution on its AI security platform growth, while risks include competitive pressures and the stock's premium pricing.

Tilray Brands Inc

TLRY trades at $4.355, down 0.57% on the day, amid a bearish technical signal and weak earnings performance. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, while revenue grew to $821.31 million. Recent news includes medical cannabis expansion in Panama and the acquisition of HelloMD to enhance digital healthcare capabilities.

The outlook remains challenging due to persistent losses and high debt levels, though low valuation ratios like P/S of 0.55 and P/B of 0.35 may attract value investors. Key risks include profitability struggles, regulatory uncertainty, and competitive pressures in the cannabis sector. Analyst sentiment is mixed, with 65% hold ratings reflecting caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About F5 Inc

F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.

Read more on FFIV

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY